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Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 9-19. 12 Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al. Recently, novel STAT3 (Signal transducer and activator of transcription 3)-activating mutations have been identified in T-cell large granular lymphocytic (T-LGL) leukemia. However, the prevalence and specificity of STAT3 mutations in other T-cell neoplasms, in which the STAT3 pathway is also active, are unknown. As such, we sequenced STAT3 in 95 diverse T-cell malignancies including T-LGL leukemia, Sezary syndrome, anaplastic large cell lymphoma (ALCL), CD30 þ lymphoproliferative disorders in the skin and other peripheral T-cell lymphomas (PTCL) to assess the prevalence of STAT3 mutations. Such mutations are present not only in T-LGL leukemia, but also in a subset of T-cell lymphomas where CD30 is highly overexpressed: two cases of CD30 þ ALK-negative ALCL, and two cases of CD30 þ PTCL. Our results demonstrate that STAT3 mutations are not only frequent in T-LGL leukemia, but also in a subset of CD30 þ T-cell lymphomas. STAT3 is a transcription factor and oncogene that has been shown to have a critical role in cellular proliferation through cytokine and growth factor pathways. 1 While disruptive mutations in STAT3 result in hyper-IgE syndrome, 2 activating mutations have been shown to be associated with a subset of cases of T-LGL leukemia, 3 as well as chronic lymphoproliferative disorders of natural killer cells. 4 STAT3 activity has also been described as augmented in other T-cell malignancies such as ALCL 5 and Sezary syndrome. 6 Given these associations, we hypothesized that activating STAT3 mutations may be present in other T-cell malignancies beyond T-LGL leukemia. Peripheral blood, bone marrow, skin and lymph node biopsy specimens of T-LGL leukemia or other T-cell neoplasms from 2000 to 2012 were reviewed, and 95 selected cases with adequate fresh, formalin-or alcohol-fixed available material used for analysis. Cases diagnosed as ALK-negative ALCL (n ¼ 12), ALK-positive ALCL (n ¼ 2), CD30 þ lymphoproliferative disorders in the skin (n ¼ 3), Sezary syndrome (n ¼ 13), T-LGL leukemia (n ¼ 36) or PTCLs (including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, NOS; n ¼ 29) were classified according to the 2008 World Health Organization criteria. Cases diagnosed as T-LGL leukemia met the following criteria: increased proportion or absolute numbers of LGLs in a peripheral blood sample for 46 months associated with a T-cell clone, and persistent cytopenias. Cases diagnosed as ALK-negative ALCL required 490% of malignant, anaplastic T cells to be strongly CD30 þ along with the presence of hallmark cells; cases showed neoplastic cells with clustering and generally sinusoidal or paracortical patterns of involvement. Cases diagnosed as CD30 þ PTCLs showed variable expression of CD30 and o70% of neoplastic cells were positive for CD30; hallmark cells were not a distinctive feature in these cases. Three skin biopsy cases diagnosed as CD30 þ lymphoproliferative disorders in the skin were submitted in consultation from other institutions, and had a differential diagnosis of primary and secondary cutaneous CD30 þ T-cell lymphomas (lymphomatoid papulosis, mycoses fungoides in large cell transformation, or ALCL); however, in one case, the differential diagnosis was narrowed to either lymphomatoid papulosis or primary cutaneous ALCL. In all tissue-based cases, neoplastic cells constituted 430% of the nucleated cells. The genomic DNA was isolated using Qiagen (Louisville, KY, USA) DNeasy Blood & Tissue Kit, and PCR amplification of STAT3 was performed using primers covering exons 19-24, corresponding to the Src homology 2 domain where all known activating mutations of STAT3 have been identified to date 3, 4 (Supplementary Table 1 ). Sequencing was performed using an ABI 3500 sequencer and all mutations were confirmed by sequencing both forward and reverse DNA strands. All T-cell malignancies studied had verified positive T-cell receptor clones by T-cell receptor-(gamma) (TRG@) and/or T-cell receptor-(beta) (TRB@).
We first sequenced 59 cases of T-cell lymphomas including ALKnegative (n ¼ 12) and ALK-positive (n ¼ 2) ALCLs, Sezary syndrome (n ¼ 13), CD30 þ lymphoproliferative disorders in the skin (n ¼ 3) and other PTCLs (n ¼ 29) to assess for the prevalence of STAT3-activating mutations in these malignancies. While all 13 cases of Sezary syndrome were negative for STAT3 mutations, two of the 12 cases of ALK-negative CD30 þ ALCL were positive for STAT3 mutations, as were two of the eight cases of CD30 þ PTCLs (Figure 1 and Supplementary Figure 1 ; Table 1 ).
Interestingly, in all four T-cell lymphoma cases positive for STAT3 mutations, CD30 was overexpressed either strongly in all cells or in the majority; though in the cases diagnosed as CD30 þ PTCLs, CD30 expression was fewer than 70% of all cells, but 450%. All CD30 þ T-cell lymphoma cases with STAT3 mutations showed areas of cellular necrosis and were highly mitotically active (420 mitoses per five high-power fields in all cases; Table 1 ). In all cases, cells were large in size, highly atypical and showed pleomorphic nuclear features (Figure 1d ). Three cases were seen in older male patients (73, 74 and 66 years old) and one in a younger female patient (33 years old), but no statistically significant association with age, anatomic site or sex was identified in cases with mutations versus those without mutation. Given the recent report of STAT3 mutations in T-LGL leukemia, we additionally sequenced STAT3 in 36 cases of clonal T-LGL leukemia, utilizing, in part, a series of well-defined patients from our previous work. 7 Four cases were positive: two harbored the Y640F mutation and two contained the D661Y mutation (Table 1 ; Supplementary Figure 1) . Eight cases of reactive T-cell LGL expansions were also analyzed, and demonstrated no mutations. All T-LGL leukemia cases positive for STAT3 mutations were associated with an absolute neutropenia (mean absolute neutrophil count ¼ 0.92 K/ml) and overall lower hemoglobin values (mean hemoglobin ¼ 12.1 g/dl) ( Table 1) . Patients were elderly with a mean age of 61 years (range: 54-68); three patients were female and one male. However, no statistically significant association with sex or age was seen with regards to cases with STAT3 mutations versus those without such mutations.
Recently, we described unique immunophenotypic signatures in subsets of T-LGL leukemia cases; notably, that many cases by flow cytometry had distinct clustered populations of neoplastic T cells with dim expression of CD8 and homogeneous expression of CD57, as well as frequent dim expression of CD5. 7 In this earlier work, we additionally found that expression of CD16 was associated with clonal T-LGL leukemia. Given these prior findings, we attempted to correlate the relationship of antigen expression in cases of T-LGL leukemia with STAT3 mutations. One case with a STAT3 mutation showed an atypical CD8 þ (dim)/CD57 þ /CD5 þ (dim) population, the remaining STAT3-mutation-positive cases showed aberrant expression of CD16 (three of the four cases), suggesting a distinct genotypicphenotypic link.
In summary, activating STAT3 mutations are not only present in T-LGL leukemia, but also seen here in several cases with distinctive aberrancies in antigen expression. Furthermore, such mutations are also seen in CD30 þ T-cell lymphomas, both CD30 þ ALK-negative ALCL and CD30 þ PTCLs, with large cells having pleomorphic nuclear features and high-proliferative indices. While the percentage of cases of T-LGL leukemia positive for STAT3 mutations here is lower than those reported by Jerez et al., 4 we note that this is likely due to differences in assays; we did not immunopurify or enrich for clonal T cells or a neoplastic population, instead analyzing bulk leukocyte populations, as our samples were not archived in a manner amenable to later performing single-cell immunopurification. Additionally, there are subtle differences in criteria for cases diagnosed as T-LGL leukemia. We defined cases of T-LGL leukemia according to the 2008 WHO, based on the increased persistence (46 months) and presence of clonal T-LGLs in patients with cytopenias; whereas a prior study reportedly also used additional criteria, whereby cases could be selected if they also had an aberrancy in immunophenotype. 4 Such a definition would likely enrich for STAT3-mutation-positive cases. Nonetheless, our overall results demonstrating the presence and location of STAT3 mutations in T-LGL leukemia, are in concordance with prior works. Finally, regarding our identification of STAT3 mutations in CD30 þ T-cell lymphomas, our study offers the possibility that STAT3 mutations are an important event in the pathogenesis of these lymphomas. Indeed, Chiarle et al. 8 found that STAT3 was required for development of lymphoma in NPM1-ALK transgenic mice, and it is possible that mutations of STAT3 have a role in development of ALK-negative lymphomas as well. 8 Whether STAT3 mutations in patients with CD30 þ T-cell lymphomas define a unique genetic subset of T-cell lymphomas or correlate with prognosis, is not yet fully clear and further studies will be required to evaluate these possibilities; though we note here that all such positive cases had high mitotic counts and large cell morphologies. Abbreviations: ALCL, anaplastic large cell lymphoma; ANC, absolute neutrophil count; HGB, hemoglobin; HPF, high-power field; PB, peripheral blood; PLT, platelet; PTCL, peripheral T-cell lymphoma; T-LGL, T-cell large granular lymphocytic leukemia; WBC, white blood cell. a This case was also associated with focal involvement (o5% of tissue) by a B-cell lymphoma.
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